Why did a promising heart drug fail? Doomed drug highlights complications of meddling with cholesterol. 1. The failure of a high-profile cholesterol drug has thrown a spotlight on the complicated machinery that regulates cholesterol levels. But many researchers remain confident that drugs to boost levels of good cholesterol are still one of the most promising means to combat spiralling heart disease. 2. Drug company Pfizer announced on 2 December that it was cancelling all clinical trials of torcetrapib, a drug designed to raise heart-protective high-density lipoproteins (HDLs). In a trial of 15000 patients, a safety board found that more people died or suffered cardiovascular problems after taking the drug plus a cholesterol-lowering statin than those in a control group who took the statin alone. 3. The news came as a kick in the teeth to many cardiologists because earlier tests in animals and people suggested it would lower rates of cardiovascular disease. There have been no red flags to my knowledge, says John Chapman, a specialist in lipoproteins and atherosclerosis at the National Institute for Health and Medical Research (INSERM) in Paris who has also studied torcetrapib. This cancellation came as a complete shock. 4. Torcetrapib is one of the most advanced of a new breed of drugs designed to raise levels of HDLs, which ferry cholesterol out of artery-clogging plaques to the liver for removal from the body. Specifically, torcetrapib blocks a protein called cholesterol ester transfer protein (CETP), which normally transfers the cholesterol from high-density lipoproteins to low density, plaque-promoting ones. Statins, in contrast, mainly work by lowering the bad low-density lipoproteins. Under pressure 5. Researchers are now trying to work out why and how the drug backfired, something that will not become clear until the clinical details are released by Pfizer. One hint lies in evidence from earlier trials that it slightly raises blood pressure in some patients. It was thought that this mild problem would be offset by the heart benefits of the drug. But it is possible that it actually proved fatal in some patients who already suffered high blood pressure. If blood pressure is the explanation, it would actually be good news for drug developers because it suggests that the problems are specific to this compound. Other prototype drugs that are being developed to block CETP work in a slightly different way and might not suffer the same downfall. 6. But it is also possible that the whole idea of blocking CETP is flawed, says Moti Kashyap, who directs atherosclerosis research at the VA Medical Center in Long Beach, California. When HDLs excrete cholesterol in the liver, they actually rely on LDLs for part of this process. So inhibiting CETP, which prevents the transfer of cholesterol from HDL to LDL, might actually cause an abnormal and irreversible accumulation of cholesterol in the body. Youre blocking a physiologic mechanism to eliminate cholesterol and effectively constipating the pathway, says Kashyap. Going up
幼儿英语Flash小故事(270)
英文睡前故事 第1集:A Chair For Baby Bear
英文睡前故事 第7集:Badly Drawn Dog
幼儿英语Flash小故事(273)
Falsh趣味英语故事:Harry'sEnglishFriends哈利的英国朋友(4)
幼儿英语Flash小故事(290)
英文睡前故事 第36集:Grizzly Dad
英文睡前故事 第27集:Eliza and the Moonchild
英文睡前故事 第28集:Emily Brown and the Thing
英文睡前故事 第45集:Lazarus the Ladybird
幼儿英语Flash小故事(287)
英文睡前故事 第17集:Celestine Drama Queen
英文睡前故事 第21集:Diamond in the Snow
英文睡前故事 第35集:Goodnight Magic Moon
幼儿英语Flash小故事(305)
英文睡前故事 第4集:A Toad Abode
幼儿英语Flash小故事(288)
英文睡前故事 第40集:How Big Is a Million
英文睡前故事 第16集:The Magic Cutlass
英文睡前故事 第6集:Anyone for Tennis
幼儿英语Flash小故事(274)
英文睡前故事 第19集:Daft Bat
幼儿英语Flash小故事(292)
英文睡前故事 第41集:How Deep is the Sea
英文睡前故事 第25集:Dont Read This Book
英文睡前故事 第20集:Delilah Darling is in the Library
幼儿英语Flash小故事(306)
英文睡前故事 第9集:Bare Bear
英文睡前故事 第29集:Evies Mad Hair Day
英文睡前故事 第18集:Click Clack Moo Cows That Type
不限 |
英语教案 |
英语课件 |
英语试题 |
不限 |
不限 |
上册 |
下册 |
不限 |